Abbvie humira cliff status 2024?

Current Status of Humira Patent Exclusivity and Biosimilar Cliff

AbbVie's Humira, a top-selling biologic medication for treating various autoimmune diseases, has faced intense competition from biosimilar alternatives since its patent exclusivity began to expire in 2023 in the European Union.

Why is this a cliff for AbbVie?

The patent cliff for Humira marks a significant decline in AbbVie's revenue, as cheaper biosimilar versions of the drug enter the market, reducing the company's market share and profit margins. The biosimilar alternatives, such as Amgen's Amjevita (adalimumab-atto) in the United States and Samsung's Hyrimoz (adalimumab-adbm) in the EU, have been approved for marketing by the relevant regulatory authorities [1].

What's the current status of Humira patent exclusivity?

The patent exclusivity for Humira in the United States began to expire on January 1, 2023, for certain dosages and formulations, allowing biosimilar manufacturers to begin marketing their versions of the drug. However, other dosages and formulations remain under patent until later in the decade. In the EU, the patent exclusivity for Humira has largely expired, allowing biosimilars to enter the market [2].

Key dates to watch:

- January 1, 2024: AbbVie faces increasing competition from biosimilars in the US market, as the company's patent exclusivity for Humira in the US continues to erode.
- 2025: The remaining patent exclusivity for certain Humira formulations is set to expire in the US.
- 2026: Amgen's Amjevita will likely face generic competition, further eroding Humira's market share [3].

Competitive landscape and impact on AbbVie:

The entry of biosimilar alternatives to Humira will continue to pressure AbbVie's market share and revenue. As more companies enter the market with their biosimilar versions, AbbVie is likely to face significant declines in revenue and a reduction in its competitive advantage in the biologic medication market.

References:

[1] DrugPatentWatch.com: Patent Information for Humira (adalimumab) [www.drugpatentwatch.com/drugs/humira-adalimumab] (Accessed on June 25, 2024).

[2] European Medicines Agency (EMA): Adalimumab [www.ema.europa.eu/en/medicines/human/EPAR/humira](Accessed on June 25, 2024).

[3] Biotechnology and Pharmaceutical News: Amjevita (adalimumab-atto) to face generic competition in the US (Accessed on June 25, 2024).

Sources:

1. DrugPatentWatch.com
2. European Medicines Agency (EMA)
3. Biotechnology and Pharmaceutical News